NCT03859141View on ClinicalTrials.gov

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)

PHASE3CompletedINTERVENTIONAL
Enrollment

2,340

Participants

Timeline

Start Date

February 6, 2018

Primary Completion Date

April 17, 2018

Study Completion Date

November 2, 2018

Conditions
Seasonal Influenza
Interventions
BIOLOGICAL

Quadrivalent influenza vaccine

One dose of quadrivalent influenza vaccine: 0.25 ml per dose containing 7.5μg antigen.

BIOLOGICAL

Quadrivalent influenza vaccine

One dose of quadrivalent influenza vaccine: 0.25 ml per dose containing 7.5μg antigen.

BIOLOGICAL

Trivalent influenza vaccine (contains B/Victoria strain)

One dose of trivalent influenza vaccine (contains B/Victoria strain): 0.25 ml per dose containing 7.5μg antigen.

BIOLOGICAL

Trivalent influenza vaccine (contains B/Yamagata strain)

One dose of trivalent influenza vaccine (contains B/Yamagata strain): 0.25 ml per dose containing 7.5μg antigen.

Trial Locations (2)

221300

Pizhou Center for Disease Prevention and Control, Pizhou

222200

Guanyun Center for Disease Prevention and Control, Lianyungang

All Listed Sponsors
lead

Sinovac Biotech Co., Ltd

INDUSTRY

NCT03859141 - Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml) | Biotech Hunter | Biotech Hunter